UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.608

Sortiert nach

Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma

PloS one, 2020-09, Vol.15 (9), p.e0238089-e0238089

2020

Volltextzugriff (PDF)

A high-throughput microfluidic nanoimmunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultralow-volume blood samples

Proceedings of the National Academy of Sciences - PNAS, 2021-05, Vol.118 (18), p.1

2021

Volltextzugriff (PDF)

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Nature communications, 2022-07, Vol.13 (1), p.4116-4116, Article 4116

2022

Volltextzugriff (PDF)

Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I–II trials

CPT: pharmacometrics and systems pharmacology, 2024-06, Vol.13 (6), p.941-953

2024

Volltextzugriff (PDF)

Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests

Journal of clinical medicine, 2020-07, Vol.9 (8), p.2369

2020

Volltextzugriff (PDF)

Comparison of platelet count results on the Sysmex XN between citrate or MgSO4 and K2 EDTA anticoagulants

International journal of laboratory hematology, 2023-02, Vol.45 (1), p.20-28

2023

Volltextzugriff (PDF)

Comparison of platelet count results on the Sysmex XN between citrate or MgSO 4 and K2 EDTA anticoagulants

International journal of laboratory hematology, 2023-02, Vol.45 (1), p.20-28

2023

Volltextzugriff (PDF)

Abstract OT2-11-02: Ameera-1 Arm 4: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with everolimus in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-11-02-OT2-11-02

2022

Volltextzugriff (PDF)

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Journal of clinical oncology, 2023-08, Vol.41 (24), p.JCO2202746-4024

2023

Volltextzugriff (PDF)

Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-11-08-OT2-11-08

2022

Volltextzugriff (PDF)

Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-17-11

2022

Volltextzugriff (PDF)

Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-11-04-OT2-11-04

2022

Volltextzugriff (PDF)

AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS1104-TPS1104

2021

Volltextzugriff (PDF)

A high-throughput microfluidic nanoimmunoassay for detecting anti–SARS-CoV-2 antibodie

Proceedings of the National Academy of Sciences - PNAS, 2021-05, Vol.118 (18), p.1

2021

Volltextzugriff (PDF)

Abstract PS17-16: Sar439859, a novel selective estrogen receptor degrader (serd), demonstrates effective and broad antitumor activity in wild-type and mutant er-positive breast cancer models

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS17-16-PS17-16

2021

Volltextzugriff (PDF)

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1058-1058

2021

Volltextzugriff (PDF)

Prevalence of Immunoglobulin G (IgG) Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Evaluation of a Rapid MEDsan IgG Test in Children Seeking Medical Care

Clinical infectious diseases, 2021-04, Vol.72 (7), p.e192-e195

2021

Volltextzugriff (PDF)

Abstract 739: Preclinical and clinical activity of SAR439859, Amcenestrant, a next generation SERD

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.739-739

2021

Volltextzugriff (PDF)

Abstract 406: Development of a gene signature assessing ER modulation by SERMs and SERDs as a target engagement biomarker for endocrine therapy in breast cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.406-406

2021

Volltextzugriff (PDF)

Diagnostic accuracy of Augurix COVID‐19 IgG serology rapid test

European journal of clinical investigation, 2020-10, Vol.50 (10), p.e13357-n/a

2020

Volltextzugriff (PDF)

Prevalence of IgG against SARS-CoV-2 and evaluation of a rapid MEDsan IgG test in children seeking medical care

Clinical infectious diseases, 2020-11

2020

Volltextzugriff (PDF)

Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

Clinical cancer research, 2013-09, Vol.19 (17), p.4832-4842

2013

Volltextzugriff (PDF)

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

Therapeutic advances in medical oncology, 2022, Vol.14, p.17588359221083956-17588359221083956

2022

Volltextzugriff (PDF)

Neologistic Jargon Sparing Numbers: A Category-specific Phonological Impairment

Cognitive neuropsychology, 1997-10, Vol.14 (7), p.1029-1061

Cohen Patrick Verstichel Stanislas Dehaene, Laurent

1997

Volltextzugriff (PDF)

1 – 25 von 2.608

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.236)
Mit Volltextzugriff
(2.329)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.538)
Life Sciences & Biomedicine
(1.257)
Humans
(1.054)
Male
(634)
Female
(628)
Adult
(390)
Middle Aged
(355)
Biological And Medical Sciences
(306)
Aged
(256)
Medical Sciences
(254)
Life Sciences
(205)
Animals
(190)
Neurosciences & Neurology
(179)
Physical Sciences
(165)
Treatment Outcome
(140)
Surgery
(138)
General & Internal Medicine
(137)
Risk Factors
(135)
Adolescent
(133)
Cardiovascular System & Cardiology
(132)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma

A high-throughput microfluidic nanoimmunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultralow-volume blood samples

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I–II trials

Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests

Comparison of platelet count results on the Sysmex XN between citrate or MgSO4 and K2 EDTA anticoagulants

Comparison of platelet count results on the Sysmex XN between citrate or MgSO 4 and K2 EDTA anticoagulants

Abstract OT2-11-02: Ameera-1 Arm 4: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with everolimus in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer

Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer

Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer

AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer

A high-throughput microfluidic nanoimmunoassay for detecting anti–SARS-CoV-2 antibodie

Abstract PS17-16: Sar439859, a novel selective estrogen receptor degrader (serd), demonstrates effective and broad antitumor activity in wild-type and mutant er-positive breast cancer models

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)

Prevalence of Immunoglobulin G (IgG) Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Evaluation of a Rapid MEDsan IgG Test in Children Seeking Medical Care

Abstract 739: Preclinical and clinical activity of SAR439859, Amcenestrant, a next generation SERD

Abstract 406: Development of a gene signature assessing ER modulation by SERMs and SERDs as a target engagement biomarker for endocrine therapy in breast cancer

Diagnostic accuracy of Augurix COVID‐19 IgG serology rapid test

Prevalence of IgG against SARS-CoV-2 and evaluation of a rapid MEDsan IgG test in children seeking medical care

Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

Neologistic Jargon Sparing Numbers: A Category-specific Phonological Impairment

Suchergebnisse filtern